

Raman Venkataramanan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8087654/publications.pdf>

Version: 2024-02-01

152
papers

9,131
citations

76322
40
h-index

42393
92
g-index

154
all docs

154
docs citations

154
times ranked

10077
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy. British Journal of Clinical Pharmacology, 2022, 88, 271-281.	2.4	10
2	Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice. Cancer Chemotherapy and Pharmacology, 2022, 89, 231-242.	2.3	3
3	Important considerations for drugs, nutritional, and herbal supplements in pediatric solid organ transplant recipients. Pediatric Transplantation, 2021, 25, e13881.	1.0	3
4	A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110136.	2.6	4
5	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	2.0	89
6	A Physiologically Based Pharmacokinetic Analysis To Predict the Pharmacokinetics of Intravenous Isavuconazole in Patients with or without Hepatic Impairment. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	3
7	An evaluation of the safety and preliminary efficacy of periâ€•and postâ€•operative treprostinil in preventing ischemia and reperfusion injury in adult orthotopic liver transplant recipients. Clinical Transplantation, 2021, 35, e14298.	1.6	8
8	Physiologically based pharmacokinetic modelling of treprostinil after intravenous injection and extendedâ€•release oral tablet administration in healthy volunteers: An extrapolation to other patient populations including patients with hepatic impairment. British Journal of Clinical Pharmacology, 2021, , .	2.4	4
9	Obstetrical, fetal, and lactation pharmacologyâ€•a crisis that can no longer be ignored. American Journal of Obstetrics and Gynecology, 2021, 225, 10-20.	1.3	20
10	Plasmapheresis Decreases Belatacept Exposure: Requires Consideration for Dose and Frequency Adjustments. Transplantation, 2021, 105, e152-e153.	1.0	1
11	Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. Frontiers in Pediatrics, 2021, 9, 733823.	1.9	17
12	A Possible Mechanism of Action of 17Î±-Hydroxyprogesterone Caproate: Enhanced IL-10 Production. American Journal of Perinatology, 2021, , .	1.4	0
13	Brand-to-Generic Substitution of Buprenorphine/Naloxone Sublingual Film in Puerto Rico: A Case Study.. Puerto Rico Health Sciences Journal, 2021, 40, 192-194.	0.2	2
14	Naltrexone use in pregnancy: a time for change. American Journal of Obstetrics and Gynecology, 2020, 222, 1-2.	1.3	18
15	Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. International Journal of Epidemiology, 2020, 49, 648-656.	1.9	21
16	Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2020, 60, 540-549.	2.0	4
17	Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations. Journal of Clinical Pharmacology, 2020, 60, 477-488.	2.0	8
18	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. Therapeutic Drug Monitoring, 2020, 42, 665-670.	2.0	22

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and Biodistribution of Tacrolimus after Topical Administration: Implications for Vascularized Composite Allotransplantation. <i>Pharmaceutical Research</i> , 2020, 37, 222.	3.5	3
20	In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 633-640.	2.3	3
21	Model-Informed Dose Optimization in Pregnancy. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S63-S76.	2.0	10
22	Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 264-270.	2.0	26
23	Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 535-545.	2.3	3
24	Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. <i>Pharmaceutics</i> , 2020, 12, 1226.	4.5	4
25	Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	18
26	Effects of Pregnancy on the Pharmacokinetics of Metformin. <i>Drug Metabolism and Disposition</i> , 2020, 48, 264-271.	3.3	31
27	Evaluation of Renal Anionic Secretion Following Living-donor and Deceased-donor Renal Transplantation: A Clinical Pharmacokinetic Study of Cefoxitin Microdosing. <i>Transplantation Direct</i> , 2020, 6, e561.	1.6	1
28	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 360-368.	2.0	48
29	Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation. <i>American Journal of Perinatology</i> , 2020, , .	1.4	1
30	Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. <i>Biomaterials</i> , 2019, 210, 25-40.	11.4	36
31	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 608-609.	1.3	0
32	Aerosolization of Second-generation Triazoles: In Vitro Evaluation and Application in Therapy of Invasive Airway Aspergillosis. <i>Transplantation</i> , 2019, 103, 2608-2613.	1.0	6
33	<i>Clinical Pharmacokinetics</i> , , 2019, , 409-424.		8
34	Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. <i>American Journal of Transplantation</i> , 2018, 18, 1527-1533.	4.7	37
35	Newly Emerging Drugs of Abuse and Their Detection Methods. <i>American Journal of Clinical Pathology</i> , 2018, 149, 105-116.	0.7	46
36	The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome. <i>Paediatric and Perinatal Epidemiology</i> , 2018, 32, 213-222.	1.7	23

#	ARTICLE	IF	CITATIONS
37	Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate. American Journal of Perinatology, 2018, 35, 809-814.	1.4	4
38	A Model of Dormant-Emergent Metastatic Breast Cancer Progression Enabling Exploration of Biomarker Signatures. Molecular and Cellular Proteomics, 2018, 17, 619-630.	3.8	43
39	Impact of Pregnancy History and 17-Hydroxyprogesterone Caproate on Cervical Cytokines and Matrix Metalloproteinases. American Journal of Perinatology, 2018, 35, 470-480.	1.4	3
40	Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	29
41	Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents. Journal of Controlled Release, 2018, 288, 212-226.	9.9	10
42	Defining the clinical response to 17-alpha hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2018, 219, 623-625.	1.3	3
43	Belatacept for maintenance immunosuppression in cardiothoracic transplantation: The potential frontier. Clinical Transplantation, 2018, 32, e13363.	1.6	7
44	Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics. Frontiers in Surgery, 2018, 5, 20.	1.4	13
45	Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2018, 84, 2075-2087.	2.4	26
46	Nausea and vomiting of pregnancy - What's new?. Autonomic Neuroscience: Basic and Clinical, 2017, 202, 62-72.	2.8	86
47	Effect of aerosolized antipseudomonas on <i>Pseudomonas</i> positivity and bronchiolitis obliterans syndrome after lung transplantation. Transplant Infectious Disease, 2017, 19, e12688.	1.7	13
48	Single Implantable FK506 Disk Prevents Rejection in Vascularized Composite Allotransplantation. Plastic and Reconstructive Surgery, 2017, 139, 403e-414e.	1.4	30
49	Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy. Journal of Controlled Release, 2017, 258, 43-55.	9.9	95
50	Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	8
51	Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. Acta Pharmacologica Sinica, 2017, 38, 823-834.	6.1	65
52	Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?. Human Immunology, 2017, 78, 64-71.	2.4	22
53	Delayed villous maturation in term placentas exposed to opioid maintenance therapy: a retrospective cohort study. American Journal of Obstetrics and Gynecology, 2017, 216, 418.e1-418.e5.	1.3	26
54	Synergistic immunosuppression and unintended consequences. Pediatric Transplantation, 2017, 21, e13047.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Deficiency of N -acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver. <i>Biochemical Pharmacology</i> , 2017, 145, 218-225.	4.4	6
56	A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2458-2473.	2.4	23
57	Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	36
58	An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 459.e1-459.e6.	1.3	41
59	Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 64.e1-64.e7.	1.3	46
60	Drug Metabolism in the Liver. <i>Clinics in Liver Disease</i> , 2017, 21, 1-20.	2.1	413
61	Mechanisms of Drug-Induced Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2017, 21, 35-54.	2.1	47
62	Drug Metabolism, Drug Interactions, and Drug-Induced Liver Injury in Living Donor Liver Transplant Patients. <i>Clinics in Liver Disease</i> , 2017, 21, 181-196.	2.1	10
63	An Elastomeric Polymer Matrix, PEUU-Tac, Delivers Bioactive Tacrolimus Transdurally to the CNS in Rat. <i>EBioMedicine</i> , 2017, 26, 47-59.	6.1	10
64	Population pharmacokinetics of 17 β -hydroxyprogesterone caproate in singleton gestation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1084-1093.	2.4	12
65	Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3558-3562.	3.2	14
66	Development and validation of a sensitive liquid chromatographic-tandem mass spectrometric method for the simultaneous analysis of granisetron and 7 α -hydroxy granisetron in human plasma and urine samples: application in a clinical pharmacokinetic study in pregnant subject. <i>Biomedical Chromatography</i> , 2016, 30, 149-154.	1.7	7
67	A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 682-689.	2.0	8
68	A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel. <i>Acta Biomaterialia</i> , 2016, 43, 282-291.	8.3	33
69	Ondansetron Exposure Changes in a Pregnant Woman. <i>Pharmacotherapy</i> , 2016, 36, e139-e141.	2.6	14
70	An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. <i>Nature Communications</i> , 2016, 7, 13443.	12.8	156
71	Polymorphisms in <i>CYP1A1</i> and <i>CYP3A5</i> Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting. <i>Pharmacotherapy</i> , 2016, 36, 1238-1244.	2.6	6
72	Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 93.e1-93.e4.	1.3	4

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of drugs in adult living donor liver transplant patients: regulatory factors and observations based on studies in animals and humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 231-243.	3.3	16
74	Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. <i>Xenobiotica</i> , 2016, 46, 169-174.	1.1	6
75	Human hepatocyte assessment of imatinib drug-drug interactions complexities in clinical translation. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1097-1108.	2.4	7
76	Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients. <i>Pediatric Transplantation</i> , 2015, 19, 911-917.	1.0	15
77	Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1042-1050.	2.4	22
78	Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. <i>Biomaterials</i> , 2015, 67, 104-114.	11.4	111
79	Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 541.e1-541.e7.	1.3	44
80	Pharmacokinetics of drugs in pregnancy. <i>Seminars in Perinatology</i> , 2015, 39, 512-519.	2.5	233
81	Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib—a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1272-1279.	2.0	6
82	An improved d- α -tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. <i>Journal of Controlled Release</i> , 2014, 196, 272-286.	9.9	57
83	Stability of hydroxyprogesterone caproate alone and in a compounded pharmaceutical product. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1120-1127.	1.0	2
84	Quality assessment of compounded 17-hydroxyprogesterone caproate. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 47.e1-47.e7.	1.3	12
85	Pharmacokinetics of Indomethacin in Pregnancy. <i>Clinical Pharmacokinetics</i> , 2014, 53, 545-551.	3.5	20
86	Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 128.e1-128.e6.	1.3	45
87	Oseltamivir for influenza in pregnancy. <i>Seminars in Perinatology</i> , 2014, 38, 503-507.	2.5	13
88	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: Pharmacologic considerations. <i>Seminars in Perinatology</i> , 2014, 38, 516-522.	2.5	19
89	Basic obstetric pharmacology. <i>Seminars in Perinatology</i> , 2014, 38, 475-486.	2.5	38
90	A microphysiological system model of therapy for liver micrometastases. <i>Experimental Biology and Medicine</i> , 2014, 239, 1170-1179.	2.4	48

#	ARTICLE	IF	CITATIONS
91	Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes. American Journal of Obstetrics and Gynecology, 2014, 211, 412.e1-412.e6.	1.3	3
92	A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials, 2014, 35, 7146-7156.	11.4	52
93	Population Pharmacokinetics of Cyclosporine in Transplant Recipients. AAPS Journal, 2013, 15, 901-912.	4.4	36
94	A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2013, 74, 126-132.	2.8	42
95	Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 569-575.	2.0	9
96	Effect of endogenous steroid hormones on 17-alpha-hydroxyprogesterone caproate metabolism. American Journal of Obstetrics and Gynecology, 2013, 208, 86.e1-86.e6.	1.3	11
97	Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	32
98	Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer. Drug Metabolism and Disposition, 2013, 41, 1843-1851.	3.3	23
99	Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica, 2012, 42, 409-416.	1.1	50
100	Development and Application of Purified Tissue Dissociation Enzyme Mixtures for Human Hepatocyte Isolation. Cell Transplantation, 2012, 21, 1245-1260.	2.5	63
101	Treprostinil Improves Hepatic Cytochrome P450 Activity during Rat Liver Transplantation. Journal of Clinical and Experimental Hepatology, 2012, 2, 323-332.	0.9	4
102	Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. American Journal of Obstetrics and Gynecology, 2012, 207, 398.e1-398.e8.	1.3	48
103	Population Pharmacokinetic Evaluation with External Validation and Bayesian Estimator of Voriconazole in Liver Transplant Recipients. Clinical Pharmacokinetics, 2011, 50, 201-214.	3.5	37
104	Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. American Journal of Obstetrics and Gynecology, 2011, 204, S84-S88.	1.3	68
105	Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. American Journal of Obstetrics and Gynecology, 2011, 205, 40.e1-40.e8.	1.3	40
106	Activation of liver X receptor increases acetaminophen clearance and prevents its toxicity in mice. Hepatology, 2011, 54, 2208-2217.	7.3	35
107	Determination of cidofovir in human plasma after low dose drug administration using high-performance liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 1015-1021.	2.8	8
108	Metabolism of 17 β -Hydroxyprogesterone Caproate, an Agent for Preventing Preterm Birth, by Fetal Hepatocytes. Drug Metabolism and Disposition, 2010, 38, 723-727.	3.3	21

#	ARTICLE	IF	CITATIONS
109	Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. <i>Transplant International</i> , 2009, 22, 554-561.	1.6	50
110	Daily Topical Tacrolimus Therapy Prevents Skin Rejection in a Rodent Hind Limb Allograft Model. <i>Plastic and Reconstructive Surgery</i> , 2009, 123, 17S-25S.	1.4	36
111	Simultaneous quantitation of 17 β -hydroxyprogesterone caproate, 17 β -hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography–mass spectrometry (HPLC–MS/MS). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 1174-1180.	2.8	33
112	Identification of Enzymes Involved in the Metabolism of 17 β -Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1896-1902.	3.3	29
113	Pharmacokinetics of Mycophenolic Acid in Live Donor Liver Transplant Patients vs Deceased Donor Liver Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 547-552.	2.0	8
114	Pharmacokinetics of Tacrolimus in Living Donor Liver Transplant and Deceased Donor Liver Transplant Recipients. <i>Transplantation</i> , 2008, 85, 554-560.	1.0	14
115	In vitro and in vivo assessment of herb drug interactions. <i>Life Sciences</i> , 2006, 78, 2105-2115.	4.3	98
116	An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 935-952.	5.6	939
117	Pharmacokinetics of Metronidazole Administered as a Single Oral Bolus to Red Rat Snakes, <i>Elaphe guttata</i> . <i>Journal of Herpetological Medicine and Surgery</i> , 2006, 16, 15-19.	0.4	13
118	Determination of 13-O-demethyl tacrolimus in human liver microsomal incubates using liquid chromatography–mass spectrometric assay (LC–MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 821, 31-37.	2.3	7
119	Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 633-639.	1.3	346
120	Activity and Expression of Various Isoforms of Uridine Diphosphate Glucuronosyltransferase are Differentially Regulated During Hepatic Regeneration in Rats. <i>Pharmaceutical Research</i> , 2005, 22, 2007-2015.	3.5	26
121	Effect of the St. John's Wort Constituent Hyperforin on Docetaxel Metabolism by Human Hepatocyte Cultures. <i>Clinical Cancer Research</i> , 2005, 11, 6972-6979.	7.0	50
122	PHARMACOKINETICS OF TACROLIMUS AND MYCOPHENOLIC ACID ARE ALTERED, BUT RECOVER AT DIFFERENT TIMES DURING HEPATIC REGENERATION IN RATS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 329-335.	3.3	13
123	INDUCTION AND INHIBITION OF CYTOCHROMES P450 BY THE ST. JOHN'S WORT CONSTITUENT HYPERFORIN IN HUMAN HEPATOCYTE CULTURES. <i>Drug Metabolism and Disposition</i> , 2004, 32, 512-518.	3.3	168
124	Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. <i>Liver Transplantation</i> , 2003, 9, 954-960.	2.4	72
125	Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3091-3093.	3.2	145
126	Pharmacokinetics of Mycophenolic Acid after Mycophenolate Mofetil Administration in Liver Transplant Patients Treated with Tacrolimus. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 268-276.	2.0	77

#	ARTICLE	IF	CITATIONS
127	Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients. Journal of Clinical Pharmacology, 2001, 41, 542-551.	2.0	140
128	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 2001, 27, 383-391.	21.4	1,954
129	Co-administration of Co-trimoxazole Does Not Augment Tacrolimus-Induced Impairment in Kidney Function in Rats. Renal Failure, 1999, 21, 635-645.	2.1	0
130	Effect of T-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transplantation, 1999, 5, 101-106.	1.8	6
131	Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation*. Clinical Pharmacology and Therapeutics, 1998, 63, 296-302.	4.7	22
132	A Quantitative Study of in vitro Hepatic Metabolism of Tacrolimus (FK506) Using Secondary Ion and Matrix-assisted Laser Desorption/Ionization Mass Spectrometry. Rapid Communications in Mass Spectrometry, 1996, 10, 1215-1218.	1.5	16
133	Tacrolimus: a new immunosuppressive agent. American Journal of Health-System Pharmacy, 1995, 52, 1521-1535.	1.0	137
134	Clinical Pharmacokinetics of Tacrolimus. Clinical Pharmacokinetics, 1995, 29, 404-430.	3.5	671
135	FK506 Measurement. Therapeutic Drug Monitoring, 1993, 15, 204-208.	2.0	27
136	Pharmacokinetics of FK506 in Liver Transplant Recipients After Continuous Intravenous Infusion. Journal of Clinical Pharmacology, 1993, 33, 606-611.	2.0	47
137	Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. American Journal of Health-System Pharmacy, 1992, 49, 119-121.	1.0	4
138	Pharmacokinetics of Ceftriaxone in Liver Transplant Recipients. Journal of Clinical Pharmacology, 1991, 31, 722-728.	2.0	11
139	The influence of liver dysfunction on cyclosporine pharmacokinetics – A comparison between 70 per cent hepatectomy and complete bile duct ligation in dogs. The Japanese Journal of Surgery, 1989, 19, 49-56.	0.2	13
140	Clinical Pharmacokinetics in Organ Transplant Patients. Clinical Pharmacokinetics, 1989, 16, 134-161.	3.5	57
141	Drug Binding Proteins in Liver Transplant Patients. Journal of Clinical Pharmacology, 1988, 28, 505-506.	2.0	15
142	Cyclosporine Kinetics in Healthy Volunteers. Journal of Clinical Pharmacology, 1987, 27, 243-248.	2.0	46
143	Blood Protein Binding of Cyclosporine in Transplant Patients. Journal of Clinical Pharmacology, 1987, 27, 240-242.	2.0	22
144	Clinical Pharmacokinetics of Cyclosporin. Clinical Pharmacokinetics, 1986, 11, 107-132.	3.5	431

#	ARTICLE	IF	CITATIONS
145	Stability and availability of cyclosporine stored in plastic syringes. American Journal of Health-System Pharmacy, 1986, 43, 692-694.	1.0	1
146	Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. American Journal of Health-System Pharmacy, 1986, 43, 2800-2802.	1.0	11
147	Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection. American Journal of Health-System Pharmacy, 1986, 43, 94-97.	1.0	0
148	Cyclosporine Absorption Following Orthotopic Liver Transplantation. Journal of Clinical Pharmacology, 1986, 26, 647-651.	2.0	55
149	Antipyrine kinetics in liver disease and liver transplantation. Clinical Pharmacology and Therapeutics, 1986, 39, 372-377.	4.7	28
150	Cyclosporine Concentration Determinations for Monitoring and Pharmacokinetic Studies. Journal of Clinical Pharmacology, 1986, 26, 358-366.	2.0	33
151	Excretion of propoxyphene and norpropoxyphene in breast milk. Clinical Pharmacology and Therapeutics, 1984, 35, 675-680.	4.7	18
152	The Clearance of Cyclosporine by Hemodialysis. Journal of Clinical Pharmacology, 1984, 24, 528-531.	2.0	35